Drug Profile
Research programme: antibody therapeutics - Harbour Biomed
Alternative Names: HCAb antibodyLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Harbour BioMed
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer